Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans.
We investigated by means of a controlled prospective study, the effect of low dose oral colchicine (1.2 mg/day) on proliferative vitreoretinopathy (PVR) in humans. The PVR cases studied included ones associated with proliferative diabetic retinopathy, sickle retinopathy, trauma, and by venous occlusive disease. Applying Sandler's A statistic for correlated samples, we found no statistically significant difference between the results achieved in the colchicine group and those in the control group (vitamin C, 250 mg/day orally). We conclude that safe dosages of this drug do not significantly inhibit PVR.